What does this research mean for the field?

Relapse following frontline blinatumomab therapy in Philadelphia chromosome-negative B-ALL is uncommon, but obesity, baseline WBC count > 50 × 10^9/L, and TP53 mutation with VAF ≥ 45% are independent predictors of relapse, which carries a dismal post-relapse prognosis. Novelty: ClaimNovelty.NOVEL_FINDING. Consensus alignment: ConsensusAlignment.SUPPORTS_CONSENSUS.

What question did this study set out to answer?

To identify predictors of relapse and post-relapse outcomes following frontline blinatumomab therapy in Ph-negative B-ALL patients.

May 20, 2026American Journal of HematologyOpen Access

Predictors of Relapse and Post‐Relapse Outcomes After Frontline Blinatumomab in Philadelphia Chromosome‐Negative B‐ ALL

View Full Paper

Ask AI

Bookmark

Authors

SASankalp AroraUniversity of Delhi HKHM KantarjianThe University of Texas MD Anderson Cancer Center KSKoji SasakiThe University of Texas MD Anderson Cancer Center

Discussion

Member takes

Implication

Retrospective study identifies relapse risk factors and post-relapse outcomes in adults with Ph-negative B-ALL.

Key Points

To identify predictors of relapse and post-relapse outcomes following frontline blinatumomab therapy in Ph-negative B-ALL patients.
Retrospective analysis of 213 patients aged ≥ 18 with newly diagnosed Ph-negative B-ALL.
Investigated relapse factors using Fine-Gray competing risk regression and survival outcomes via Kaplan-Meier method.
Excluded patients receiving blinatumomab for MRD positive recurrence.
11% of patients relapsed after median follow-up of 36.7 months, with a 2-year cumulative incidence of relapse of 11.4%.
Obesity, WBC count > 50 × 109/L, and TP53 mutation VAF ≥ 45% were independent predictors of increased relapse risk.
Post-relapse median overall survival was only 7 months, highlighting poor outcomes.

Cite This Study

Arora et al. (2026) studied this question.

synapsesocial.com/papers/6a0d4ec0f03e14405aa99e76 https://doi.org/10.1002/ajh.70353

View Full Paper

Ask AI

Bookmark

Predictors of Relapse and Post‐Relapse Outcomes After Frontline Blinatumomab in Philadelphia Chromosome‐Negative B‐ ALL

Discussion

Member takes

Implication

Key Points

Cite This Study

Predictors of Relapse and Post‐Relapse Outcomes After Frontline Blinatumomab in Philadelphia Chromosome‐Negative B‐ ALL

Discussion

Member takes

Implication

Key Points

Cite This Study

Also Consider

Also Consider